Nevertheless, because the mechanistic role of atezolizumab is restricted to tumor recognition by T cells, the application of our model to other ICI therapies, such as anti–PD-1 and anti–CTLA-4 therapies, remains to be tested. Here, PDCD1 is linked to neoplasm.